Contract Manufacturing Pharmaceutical Company in India: Complete Guide (2025–2026)

admin
22nd, June 2026

Categories

Tags

You May Also Like

Introduction

The global pharmaceutical industry has fundamentally shifted toward outsourcing — and at the heart of this shift is the contract manufacturing pharmaceutical company, or CDMO (Contract Development and Manufacturing Organization). Rather than building and operating their own manufacturing infrastructure, pharmaceutical companies of all sizes are partnering with specialized contract manufacturers to produce APIs, formulations, biologics, and packaging at scale, speed, and lower cost.

India has emerged as the world’s most strategic destination for pharmaceutical contract manufacturing. The India CDMO market was valued at USD 8.52 billion in 2025 and is projected to reach USD 16.53 billion by 2034, growing at a CAGR of 7.39%. Driven by India’s deep generics manufacturing heritage, world-class regulatory compliance, and cost-competitive infrastructure, Indian CDMOs now serve global pharmaceutical companies from startups to multinational innovators.

This guide explains exactly what pharmaceutical contract manufacturing is, what services it covers, how to evaluate a CDMO partner, the top companies in India, and why Salvavidas Pharmaceutical Pvt. Ltd. is a trusted choice for businesses seeking a reliable manufacturing partner.

What Is a Contract Manufacturing Pharmaceutical Company (CDMO)?

A Contract Development and Manufacturing Organization (CDMO) — or Contract Manufacturing Organization (CMO) — is a company that provides pharmaceutical manufacturing services to other pharmaceutical companies on a contractual basis. Rather than the client building their own facility, the CDMO manufactures products on their behalf, using the client’s formula, or developing the formulation and manufacturing it end-to-end.

Core Services Offered by a Pharmaceutical Contract Manufacturer:

*API Manufacturing — Production of Active Pharmaceutical Ingredients (bulk drugs)

*Finished Dosage Form (FDF) Manufacturing — Tablets, capsules, injectables, syrups, topicals

*Formulation Development — Creating and optimizing drug formulations for stability and bioavailability

Process Development — Scaling laboratory processes to commercial manufacturing

*Packaging Services — Primary and secondary packaging, labeling, serialization

*Analytical & Regulatory Support — Quality testing, stability studies, regulatory dossier preparation

*Clinical Supply Manufacturing — Small-scale production for clinical trials

India's Pharmaceutical Contract Manufacturing Market: Key Numbers (2025–2026)

Contract manufacturing services dominate India’s CDMO market with a 53.8% share in 2025, driven by strong demand for API production, finished dosage form manufacturing, and biologics outsourcing.

Metric Data
India CDMO Market Value (2025) USD 8.52 Billion – USD 25.51 Billion*
Projected Market Value (2034–2035) USD 16.53 Billion – USD 71.14 Billion*
CAGR (2026–2034) 7.39% – 10.80%*
Contract Manufacturing Share 53.8% of total CDMO market
Small Molecule Dominance 67.2% of India CDMO market
Sterile Injectable CAGR (Global) 9.05% through 2031
Oncology Segment Share 32.15% of global CDMO revenue
API Segment Share 51.78% – 54.92% of revenue

Range reflects varying estimates across multiple market research sources.

India’s CDMO market is driven by a large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry. It is expected to grow at a CAGR of 10.80% during 2026–2035 and attain a market value of USD 71.14 billion by 2035.

Why India Is the World's Most Preferred Pharmaceutical Contract Manufacturing Destination

1. Deep Generics Manufacturing Heritage

India is the world’s largest producer of generic drugs, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand — well-positioned to meet this demand through its robust CDMO infrastructure.

2. Significant Cost Advantage

India’s ability to offer low-cost manufacturing without compromising on quality has positioned it as a preferred destination for pharmaceutical outsourcing. The country benefits from lower labor costs, reduced operational expenses, and economies of scale, making it highly competitive compared to Western countries.

3. Regulatory Alignment with Global Standards

India holds more USFDA-approved manufacturing facilities outside the US than any other country. Indian CDMOs’ adherence to international regulatory standards, coupled with their ability to provide end-to-end solutions from research and development to manufacturing, attracts global pharmaceutical companies.

4. "China Plus One" Strategic Advantage

The U.S. Congress passed the “BIOSECURE Act” restricting federal contracts with certain foreign biotech firms, prompting U.S. pharma companies to shift contracts from China to India — creating a massive tailwind for Indian CDMOs as “China Plus One” beneficiaries.

5. Government Policy Support

India’s Production Linked Incentive (PLI) scheme, the Make in India initiative, and harmonized regulatory standards continue to attract both domestic and foreign investment into pharmaceutical contract manufacturing — reducing barriers and increasing global competitiveness.

6. Skilled Scientific Workforce

Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance — now being applied to more advanced services including biologics, cell and gene therapies, and niche formulations.

Types of Pharmaceutical Contract Manufacturing Services in India

API Contract Manufacturing

The largest segment of India’s CDMO market, covering synthesis and production of Active Pharmaceutical Ingredients for generic and branded drug manufacturers worldwide. Small molecules exhibit clear dominance with a 67.2% share of the total India CDMO market in 2025.

Finished Dosage Form (FDF) Contract Manufacturing

Production of ready-to-dispense pharmaceutical formulations:

*Solid orals — Tablets, capsules, sachets

*Liquid orals — Syrups, suspensions, dry syrups

*Sterile injectables — Ampoules, vials, pre-filled syringes

*Topicals — Creams, ointments, transdermal patches

*Inhalers — MDIs, dry powder inhalers

Biologics & Biosimilar Contract Manufacturing

Large molecules/biologics are projected to grow at a 15.26% CAGR, challenging small-molecule dominance — with Indian CDMOs investing in mammalian cell culture, monoclonal antibody production, and single-use bioreactor systems.

Third-Party / Private Label Manufacturing

Businesses without their own manufacturing infrastructure outsource production under their own brand name. This model is widely used by:

*PCD (Propaganda Cum Distribution) pharma franchise businesses

*Regional and national pharmaceutical distributors

*New pharma brands entering the market without capital-intensive facility investment

*International importers and distributors in semi-regulated markets

High-Potency API (HPAPI) Manufacturing

HPAPIs are projected to grow at an 8.05% CAGR to 2031 — driven by the expansion of oncology drug pipelines requiring specialized containment manufacturing capabilities.

How to Choose the Right Contract Manufacturing Pharmaceutical Company

Selecting a CDMO partner is one of the most consequential supply-chain decisions a pharmaceutical company will make. Here is the evaluation framework experienced buyers use:

1. Regulatory Certifications

Confirm the facility holds WHO-GMP as a minimum standard. For regulated market access, look for USFDA, EU-GMP, TGA, or ANVISA approvals matching your target markets.

2. Service Scope & Capabilities

Clarify upfront whether you need API manufacturing, FDF manufacturing, formulation development, packaging, or end-to-end CDMO services. Not all contract manufacturers offer all services.

3. Therapeutic Area Experience

A manufacturer with prior experience in your therapeutic category (oncology, cardiovascular, anti-infective, etc.) brings process knowledge and stability data that significantly reduces your development risk.

4. Quality Management Systems

Look for dedicated QA/QC teams, validated analytical methods, stability testing capabilities, and documented batch manufacturing records (BMRs).

5. Regulatory Affairs Support

The best contract manufacturing partners provide full documentation support — CoA, COPP, Free Sale Certificate, DMF/dossier preparation — to facilitate product registration in your destination market.

6. Production Capacity & Scalability

Verify the facility’s current capacity utilization and ability to scale production as your business grows.

7. Intellectual Property Protection

Ensure robust confidentiality agreements (NDAs) and IP protection protocols are in place before sharing formulation data or proprietary processes.

8. Communication & Project Management

Responsive, transparent communication and a dedicated project manager are hallmarks of a CDMO that treats your business as a genuine partnership.

9. Inspection Track Record

Request recent regulatory inspection outcomes. There has been a 32% increase in warning letters issued to pharmaceutical manufacturers for GMP violations globally — a clean inspection history is a powerful differentiator.

10. Pricing Transparency

Request detailed, itemized quotations. Hidden costs in raw materials, testing, or documentation are a common source of commercial friction with less reputable contract manufacturers.

Top Contract Manufacturing Pharmaceutical Companies in India (2025–2026)

1. Salvavidas Pharmaceutical Pvt. Ltd. — Surat, Gujarat ⭐ Recommended Partner

Salvavidas Pharmaceutical Pvt. Ltd. is a WHO-GMP certified pharmaceutical manufacturer based in Surat, Gujarat, offering reliable contract and third-party manufacturing services across APIs, finished formulations, and intermediates. For pharmaceutical businesses — from established distributors to new entrants building their product portfolio — Salvavidas provides the manufacturing backbone that combines quality compliance with flexible, client-focused service.

What Makes Salvavidas the Right Contract Manufacturing Partner:

Feature Details
Certification WHO-GMP Certified
Manufacturing Range APIs, Finished Formulations, Dry Syrups, Injectables, Intermediates
Therapeutic Areas Oncology, Neurology, Cardiovascular, Anti-infective & more
Markets Served Asia, Africa, Europe, Middle East
Third-Party Manufacturing Available — including private label support
Documentation Support CoA, COPP, Free Sale Certificate, GMP Certificates
Sustainability Eco-friendly manufacturing practices
Client Approach Long-term partnership, responsive communication

Salvavidas’s combination of WHO-GMP certified quality, broad therapeutic range, and willingness to work closely with each client makes it a practical and dependable choice — especially for businesses that need more than just a factory, but a partner who understands their market and supports their growth.

🏭 Ready to outsource your pharmaceutical manufacturing to a trusted partner? Contact Salvavidas Pharmaceutical Pvt. Ltd. for product range, capacity details, and documentation support. 📧 info@salvavidas.com

2. Aurobindo Pharma — Hyderabad, Telangana

One of India’s largest pharmaceutical companies and a leading CDMO, Aurobindo offers comprehensive contract manufacturing across anti-infectives, cardiovascular, CNS, and sterile injectables for global clients across 150+ countries.

3. Dr. Reddy's Laboratories — Hyderabad, Telangana

Dr. Reddy’s has launched a dedicated “Digital CDMO” platform offering clients real-time visibility into project timelines and quality data — reflecting its investment in transparency and operational excellence as a contract manufacturing partner.

4. Syngene International — Bengaluru, Karnataka

A leading CRDMO (Contract Research, Development and Manufacturing Organization) offering integrated services across discovery chemistry, biology, safety assessment, and commercial manufacturing for global pharma and biotech clients.

5. Laurus Labs — Hyderabad, Telangana

Laurus Synthesis, a subsidiary of Laurus Labs, specializes in custom synthesis, process development, and manufacturing of niche APIs and intermediates — including high-potency APIs and complex chemistry for early-to-late stage development.

6. Cipla Ltd. — Mumbai, Maharashtra

Cipla has produced 200+ generics and complex APIs and serves as a preferred manufacturing partner for international pharmaceutical companies, particularly in HIV/AIDS medications, respiratory, and cancer treatments.

7. Lupin Manufacturing Solutions (LMS) — Mumbai, Maharashtra

Lupin entered the dedicated CDMO business in 2024 through its newly formed subsidiary, Lupin Manufacturing Solutions — leveraging Lupin’s existing manufacturing excellence to offer contract services across complex generics and specialty segments.

8. Divi's Laboratories — Hyderabad, Telangana

A specialist in contract API synthesis and custom chemistry, Divi’s serves global innovator and generic pharma companies requiring high-purity molecules and complex synthesis — particularly for cardiovascular and CNS drug categories.

9. Shilpa Medicare — Raichur, Karnataka

A fast-growing full-service hybrid CDMO with a strong oncology focus, Shilpa Medicare launched expanded small molecule, large molecule, and peptide manufacturing capabilities in 2025.

10. Intas Pharmaceuticals — Ahmedabad, Gujarat

With strong EU-GMP credentials and a biosimilar manufacturing portfolio, Intas serves as a preferred contract partner for European government tenders and oncology/renal care formulations.

Emerging Trends in India's Pharmaceutical Contract Manufacturing

Biologics & Biosimilar Manufacturing Surge

Rising demand for complex biologics, global expansion strategies by Indian CDMOs, and increasing collaborations are driven by regulatory alignment with major markets like the U.S. and EU — now being applied to more advanced services, including biologics, cell and gene therapies, and niche formulations like antibody-drug conjugates (ADCs).

Continuous Manufacturing Adoption

With increasing demand for biologics, biosimilars, and advanced therapeutics, India’s CDMOs are investing in technological advancements such as continuous manufacturing and bioprocessing to stay ahead.

AI & Digital Quality Management

AI-enabled predictive analytics, continuous-manufacturing skids, and single-use bioreactors are becoming table stakes — and quality culture remains the ultimate gatekeeper, with firms receiving zero-483 observations post-inspection converting that clean track record into premium pricing.

Oncology Focus

Oncological diseases are projected to hold the largest market share in India’s CDMO sector due to the escalating cancer burden and growing demand for advanced therapeutics — with India’s robust capabilities in developing and manufacturing complex generics, biosimilars, and antibody-drug conjugates attracting global pharmaceutical companies.

China Plus One" Driven Growth

The BIOSECURE Act and broader geopolitical realignment continue to drive Western pharmaceutical companies toward India as a strategic alternative to Chinese CDMO sourcing — a structural tailwind that will benefit Indian contract manufacturers through 2030 and beyond.

Frequently Asked Questions (FAQs)

Q1. What is the difference between a CMO and a CDMO?
A CMO (Contract Manufacturing Organization) focuses purely on manufacturing services. A CDMO (Contract Development and Manufacturing Organization) provides both development services (formulation development, process development) and manufacturing — offering a more comprehensive, end-to-end partnership.
Q2. Is third-party pharma manufacturing the same as contract manufacturing?
In India, “third-party manufacturing” typically refers specifically to producing finished pharmaceutical products under a client’s brand name — which is a subset of contract manufacturing. Contract manufacturing is the broader term encompassing API production, formulation development, custom synthesis, and more.
Q3. Do I need my own drug license to outsource pharmaceutical manufacturing in India?
Yes. Even when using a contract manufacturer, the marketing company typically needs its own drug licenses, import-export codes, and regulatory approvals for the markets where the product will be sold. The contract manufacturer provides product-specific documentation (CoA, COPP, GMP certificates).
Q4. What is the minimum order quantity (MOQ) for pharmaceutical contract manufacturing in India?
MOQs vary by product, dosage form, and manufacturer. Smaller CDMOs and specialized third-party manufacturers typically offer more flexible MOQs than large integrated pharma companies — making them better suited for new product launches or businesses with moderate volume requirements.
Q5. How do I protect my formulation IP when working with a contract manufacturer?
Always execute a comprehensive Non-Disclosure Agreement (NDA) and Manufacturing Services Agreement (MSA) before sharing any proprietary formulation data. Reputable CDMOs have established IP protection protocols and will readily provide standard NDA documentation.
Q6. How long does it typically take to start production with a contract manufacturer?
Timelines depend on whether formulation development is needed. For products with existing formulations using established manufacturing processes, commercial production can typically begin within 3–6 months. New formulation development and regulatory registrations extend this timeline.

Conclusion

The contract manufacturing pharmaceutical company model has permanently transformed how the global pharma industry operates — giving businesses of all sizes access to world-class manufacturing without the capital burden of building their own infrastructure. India’s CDMO market is experiencing robust expansion driven by increasing pharmaceutical outsourcing, a well-established generics manufacturing base, and growing global demand for cost-effective drug development solutions.

For businesses evaluating contract manufacturing pharmaceutical companies in India, the decision comes down to three things: the right regulatory credentials, the right manufacturing capabilities for your product category, and a partner who will treat your business with the care and responsiveness it deserves.

Salvavidas Pharmaceutical Pvt. Ltd. delivers on all three — WHO-GMP certified manufacturing, a comprehensive product portfolio across therapeutic categories, and a genuinely partnership-focused approach that makes it an ideal contract manufacturing partner for both established businesses and new market entrants.

Build your pharmaceutical business on a foundation of quality and trust. Partner with Salvavidas Pharmaceutical Pvt. Ltd. — your contract manufacturing pharmaceutical partner in India.